Selective JAK1 Inhibition — Rinvoq & Cibinqo
Both drugs plug the JAK1 ATP-binding pocket to stop cytokine signal relay.
- JAK1: Upadacitinib target (Rinvoq, selective)
- JAK1: Abrocitinib target (Cibinqo, selective)
- IL-4/13/31: Key cytokines blocked (Th2 + itch axis)
- Oral daily: Dosing (once-daily pill)
Mechanism snapshot
Short placeholder: JAK1 blockade halts STAT phosphorylation cascade.
Placeholder callout: selectivity for JAK1 limits off-target cytokine effects.
Itch Control Within Days
Pruritus NRS scores fall noticeably within the first days of therapy.
- ~2 days: Itch drop onset (placeholder timing)
- ~50%: NRS reduction wk1 (placeholder estimate)
- topical steroids: Faster than (placeholder comparison)
- IL-31 blockade: Driven by (nerve signaling axis)
Itch timeline
Short placeholder: itch relief precedes visible skin clearance.
Placeholder callout: rapid itch relief improves sleep and quality of life early.
EASI Clearance Over the Treatment Course
Skin clearance builds progressively across weeks of continued dosing.
- ~65%: EASI-75 by wk16 (placeholder estimate)
- ~wk12–16: Response plateau (placeholder timing)
- yes: Dose-dependent (higher dose, faster clearance)
- continued dosing: Maintenance (placeholder)
Clearance trajectory
Short placeholder: clearance curve rises steadily then plateaus.
Placeholder callout: sustained blockade needed to maintain clearance.
CBC, Lipid and Liver Enzyme Surveillance
Routine labs track cytopenia, lipid shifts and hepatic enzyme changes.
- baseline+periodic: CBC schedule (placeholder cadence)
- wk4, then periodic: Lipid panel (placeholder cadence)
- periodic: LFTs (placeholder cadence)
- lymphopenia, LDL rise: Key flags (placeholder)
Monitoring cadence
Short placeholder: labs checked at baseline and on a periodic schedule.
Placeholder callout: dose adjustment or hold considered on abnormal labs.
Weighing Benefit vs Boxed-Warning Risk
Refractory eczema cases weigh fast control against class safety warnings.
- yes: Boxed warning (JAK class label)
- refractory AD: Typical use (after other therapies)
- CV, clot, malignancy: Risk categories (placeholder class risks)
- required: Shared decision (patient-clinician discussion)
Decision framework
Short placeholder: benefit-risk assessed per patient before starting.
Placeholder callout: reserved for patients failing other systemic options.